End-of-day quote
Other stock markets
|
||
- USD | - |
09/05 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
09/05 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |